JP7649386B2 - 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 - Google Patents

哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 Download PDF

Info

Publication number
JP7649386B2
JP7649386B2 JP2023553045A JP2023553045A JP7649386B2 JP 7649386 B2 JP7649386 B2 JP 7649386B2 JP 2023553045 A JP2023553045 A JP 2023553045A JP 2023553045 A JP2023553045 A JP 2023553045A JP 7649386 B2 JP7649386 B2 JP 7649386B2
Authority
JP
Japan
Prior art keywords
mmol
compound
mixture
item
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023553045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509818A5 (https=
JP2024509818A (ja
Inventor
ジー ブラウン，ディーン
エル ヘンダーソン，ジャクリン
ムンシピント，ジョヴァンニ
イー ツヴァイク，ジョシュア
ヴィー グエン，ロング
プーレン，ニコラス
ティー アンタレク，ミッチェル
エー ホリボー，ライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jnana Therapeutics (United States)
Original Assignee
Jnana Therapeutics (United States)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jnana Therapeutics (United States) filed Critical Jnana Therapeutics (United States)
Publication of JP2024509818A publication Critical patent/JP2024509818A/ja
Publication of JP2024509818A5 publication Critical patent/JP2024509818A5/ja
Priority to JP2025036310A priority Critical patent/JP7797723B2/ja
Application granted granted Critical
Publication of JP7649386B2 publication Critical patent/JP7649386B2/ja
Priority to JP2025088466A priority patent/JP7731021B1/ja
Priority to JP2025135673A priority patent/JP2026000898A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2023553045A 2021-03-10 2022-03-09 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤 Active JP7649386B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2025036310A JP7797723B2 (ja) 2021-03-10 2025-03-07 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025088466A JP7731021B1 (ja) 2021-03-10 2025-05-28 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025135673A JP2026000898A (ja) 2021-03-10 2025-08-18 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163159271P 2021-03-10 2021-03-10
US63/159,271 2021-03-10
US202163226551P 2021-07-28 2021-07-28
US63/226,551 2021-07-28
US202163234487P 2021-08-18 2021-08-18
US63/234,487 2021-08-18
US202163292815P 2021-12-22 2021-12-22
US63/292,815 2021-12-22
US202263308790P 2022-02-10 2022-02-10
US63/308,790 2022-02-10
PCT/US2022/019513 WO2022192370A1 (en) 2021-03-10 2022-03-09 Small molecule inhibitors of mammalian slc6a19 function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036310A Division JP7797723B2 (ja) 2021-03-10 2025-03-07 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤

Publications (3)

Publication Number Publication Date
JP2024509818A JP2024509818A (ja) 2024-03-05
JP2024509818A5 JP2024509818A5 (https=) 2025-02-19
JP7649386B2 true JP7649386B2 (ja) 2025-03-19

Family

ID=83227044

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023553045A Active JP7649386B2 (ja) 2021-03-10 2022-03-09 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025036310A Active JP7797723B2 (ja) 2021-03-10 2025-03-07 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025088466A Active JP7731021B1 (ja) 2021-03-10 2025-05-28 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025135673A Pending JP2026000898A (ja) 2021-03-10 2025-08-18 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2025036310A Active JP7797723B2 (ja) 2021-03-10 2025-03-07 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025088466A Active JP7731021B1 (ja) 2021-03-10 2025-05-28 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
JP2025135673A Pending JP2026000898A (ja) 2021-03-10 2025-08-18 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤

Country Status (18)

Country Link
US (5) US20240208923A1 (https=)
EP (1) EP4304586A4 (https=)
JP (4) JP7649386B2 (https=)
KR (1) KR20230162935A (https=)
AU (1) AU2022234302A1 (https=)
CA (1) CA3209914A1 (https=)
CL (1) CL2023002581A1 (https=)
CO (1) CO2023013218A2 (https=)
CR (1) CR20230467A (https=)
DO (1) DOP2023000178A (https=)
EC (1) ECSP23075523A (https=)
IL (1) IL305262A (https=)
MX (1) MX2023010467A (https=)
PE (2) PE20260125A1 (https=)
PY (1) PY2216888A (https=)
TN (1) TN2023000216A1 (https=)
UY (1) UY39667A (https=)
WO (1) WO2022192370A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304586A4 (en) 2021-03-10 2025-04-02 Jnana Therapeutics Inc. SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION
CN117813307A (zh) 2021-08-18 2024-04-02 新锐思生物制药股份有限公司 白介素-1受体相关激酶的双官能降解物及其治疗用途
JP2025500308A (ja) * 2021-12-22 2025-01-09 ジュニャーナ セラピューティクス インコーポレイテッド 哺乳類ｓｌｃ６ａ１９機能の小分子阻害剤
AU2023342603A1 (en) * 2022-09-14 2025-04-17 Jnana Therapeutics Inc. Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function
EP4622960A1 (en) * 2022-11-22 2025-10-01 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
EP4626420A1 (en) * 2022-11-30 2025-10-08 Jnana Therapeutics Inc. Crystalline forms of a piperidine inhibitor of slc6a19 function
KR20260022325A (ko) * 2023-06-14 2026-02-19 제이나나 테라퓨틱스 인코포레이티드 Slc6a19 기능의 피페리딘 억제제
CN121399098A (zh) 2023-06-30 2026-01-23 赛诺菲 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法
CN121666235A (zh) * 2023-08-11 2026-03-13 杰那医疗公司 Slc6a19功能的含双环杂芳基的哌啶抑制剂
TW202515556A (zh) * 2023-08-17 2025-04-16 美商杰那醫療公司 Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑
WO2025049658A1 (en) * 2023-08-30 2025-03-06 Agios Pharmaceuticals, Inc. 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine derivatives as mutant pah protein stabilizers for the treatment of phenylketonuria
US20250346567A1 (en) * 2024-05-13 2025-11-13 Pfizer Inc. Substituted pyridine and phenyl compounds
WO2026038155A1 (en) * 2024-08-16 2026-02-19 Pfizer Inc. Substituted pyridine compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
FR2793248B1 (fr) 1999-05-03 2001-06-29 Adir Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000076512A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
WO2003037894A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
US20040142416A1 (en) 2002-04-30 2004-07-22 Laipis Philip J. Treatment for phenylketonuria
WO2007030761A2 (en) * 2005-09-08 2007-03-15 Smithkline Beecham Corporation Acyclic 1,4-diamines and uses thereof
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0721451A2 (pt) 2007-03-13 2014-03-25 Arete Therapeutics Inc Compostos de 4-piperidiniluréia como inibidores de epóxido hidrolase solúvel
FR2944206B1 (fr) 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
WO2011060397A1 (en) 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
WO2011060396A1 (en) 2009-11-16 2011-05-19 Schering Corporation Aliphatic amines based heterocycles useful as hiv entry blockers
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
CN104470914A (zh) 2012-06-20 2015-03-25 桑多斯股份公司 替拉瑞韦和波普瑞韦或者其药学上可接受的盐或溶剂合物和中间产物包括经Mukaiyama羟醛加成制备的β-氨基酸的合成
WO2014144130A2 (en) * 2013-03-15 2014-09-18 Als Mountain Llc Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
US9783504B2 (en) * 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
TWI703130B (zh) 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
CN117050032A (zh) * 2016-12-15 2023-11-14 阿瑞雅德制药公司 作为c-kit抑制剂的氨基噻唑化合物
WO2019040106A2 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
WO2019046303A1 (en) * 2017-08-28 2019-03-07 The Trustees Of Columbia University In The City Of New York METHOD FOR PREDICTING PATIENT RESPONSE TO SLC MODULATOR PROCESSING
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
EP3866798A4 (en) 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
CN111978311B (zh) 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AU2020308862B2 (en) 2019-06-28 2026-03-26 Research Triangle Institute Urea derivatives as CB1 allosteric modulators
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
BR112023015061A2 (pt) 2021-01-27 2023-10-03 Corteva Agriscience Llc Compostos antiparasitários
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
EP4304586A4 (en) 2021-03-10 2025-04-02 Jnana Therapeutics Inc. SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
EP4376840A4 (en) 2021-07-28 2025-05-21 Nura Bio, Inc. SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
WO2023023532A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
CN117813307A (zh) 2021-08-18 2024-04-02 新锐思生物制药股份有限公司 白介素-1受体相关激酶的双官能降解物及其治疗用途
WO2023079294A1 (en) 2021-11-05 2023-05-11 Sitryx Therapeutics Limited Phthalazine derivatives as pyruvate kinase modulators
JP2025500308A (ja) 2021-12-22 2025-01-09 ジュニャーナ セラピューティクス インコーポレイテッド 哺乳類ｓｌｃ６ａ１９機能の小分子阻害剤
EP4452982A1 (en) 2021-12-22 2024-10-30 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
US20250163022A1 (en) 2021-12-22 2025-05-22 Synnovation Therapeutics, Inc. Parp1 inhibitors
EP4452980A1 (en) 2021-12-22 2024-10-30 Chiesi Farmaceutici S.p.A. Triazolone derivative salt as neutrophil elastase inhibitor
MX2024007744A (es) 2021-12-22 2024-07-01 Sitryx Therapeutics Ltd Derivados de ftalazina como moduladores de piruvato quinasa.
EP4452253A4 (en) 2021-12-23 2026-04-15 The Katholieke Univ Leuven 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
WO2024015574A1 (en) 2022-07-14 2024-01-18 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
EP4554584A2 (en) 2022-07-14 2025-05-21 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
JP2025531160A (ja) 2022-09-14 2025-09-19 ジュニャーナ セラピューティクス インコーポレイテッド Ｓｌｃ６ａ１９機能のスピロ置換ピペリジン阻害剤及び他のピペリジン阻害剤によるｐｋｕの処置
WO2024059005A1 (en) 2022-09-14 2024-03-21 Jnana Therapeutics Inc. Treating pku with correctors of mammalian slc6a19 function
AU2023342603A1 (en) 2022-09-14 2025-04-17 Jnana Therapeutics Inc. Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function
EP4622960A1 (en) 2022-11-22 2025-10-01 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
EP4626420A1 (en) 2022-11-30 2025-10-08 Jnana Therapeutics Inc. Crystalline forms of a piperidine inhibitor of slc6a19 function
KR20260022325A (ko) 2023-06-14 2026-02-19 제이나나 테라퓨틱스 인코포레이티드 Slc6a19 기능의 피페리딘 억제제
CN121666235A (zh) 2023-08-11 2026-03-13 杰那医疗公司 Slc6a19功能的含双环杂芳基的哌啶抑制剂
TW202515556A (zh) 2023-08-17 2025-04-16 美商杰那醫療公司 Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aditya Yadav, et al.，Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases，Frontiers in Pharmacology，2020年，Vol.11, Article 140，p.1-13
CAS REGISTRY No. 2248674-20-4，DATABASE REGISTRY，2018年11月16日，[online], 2025年2月28日検索, Retrived from: STN
CAS REGISTRY No. 2254642-37-8，DATABASE REGISTRY，2019年01月03日，[online], 2025年2月28日検索, Retrived from: STN

Also Published As

Publication number Publication date
US20250289797A1 (en) 2025-09-18
TN2023000216A1 (en) 2025-04-03
US20260001859A1 (en) 2026-01-01
JP2026000898A (ja) 2026-01-06
US20250289798A1 (en) 2025-09-18
ECSP23075523A (es) 2024-01-31
CL2023002581A1 (es) 2024-02-16
US12595244B2 (en) 2026-04-07
DOP2023000178A (es) 2023-12-29
WO2022192370A1 (en) 2022-09-15
JP2025098065A (ja) 2025-07-01
UY39667A (es) 2022-10-31
CA3209914A1 (en) 2022-09-15
EP4304586A1 (en) 2024-01-17
JP2025133739A (ja) 2025-09-11
IL305262A (en) 2023-10-01
US12319668B2 (en) 2025-06-03
EP4304586A4 (en) 2025-04-02
MX2023010467A (es) 2023-11-22
US20240208923A1 (en) 2024-06-27
CO2023013218A2 (es) 2024-02-05
JP7797723B2 (ja) 2026-01-13
BR112023018277A2 (pt) 2024-01-16
JP7731021B1 (ja) 2025-09-03
AU2022234302A1 (en) 2023-10-12
JP2024509818A (ja) 2024-03-05
PE20231987A1 (es) 2023-12-12
KR20230162935A (ko) 2023-11-29
TW202302575A (zh) 2023-01-16
PY2216888A (es) 2023-09-15
PE20260125A1 (es) 2026-01-16
US20250115570A1 (en) 2025-04-10
CR20230467A (es) 2024-02-20

Similar Documents

Publication Publication Date Title
JP7649386B2 (ja) 哺乳動物ｓｌｃ６ａ１９機能の小分子阻害剤
US20250084054A1 (en) Small molecule inhibitors of mammalian slc6a19 function
JP2025531160A (ja) Ｓｌｃ６ａ１９機能のスピロ置換ピペリジン阻害剤及び他のピペリジン阻害剤によるｐｋｕの処置
JP2025531154A (ja) 哺乳類ｓｌｃ６ａ１９機能のコレクターを用いるｐｋｕの処置
JP2025540072A (ja) Ｓｌｃ６ａ１９機能のピペリジン阻害剤の結晶形態
JP2025524655A (ja) 哺乳動物のｓｌｃ６ａ１９機能に対する低分子阻害剤
TW202515556A (zh) Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑
TW202515554A (zh) Slc6a19功能之含雙環雜芳基之哌啶抑制劑
JP2025523074A (ja) 哺乳動物のｓｌｃ６ａ１９機能に対する低分子阻害剤
IL325059A (en) Piperidine inhibitor of slc6a19 function
WO2022020247A1 (en) Small molecule correctors of mammalian slc6a8 function
BR122025025720A2 (pt) Composições farmacêuticas compreendendo compostos inibidores de pequenas moléculas da função de slc6a19 de mamíferos
BR112023018277B1 (pt) Compostos inibidores de pequenas moléculas da função de slc6a19 de mamíferos, e seu uso
CN117015378A (zh) 哺乳动物slc6a19功能的小分子抑制剂
WO2022221182A1 (en) Small molecule inhibitors of mammalian slc34a1 function
WO2026050147A1 (en) Diaminomethylene-containing agonists of the parathyroid hormone 1 receptor
HK40102700A (zh) 哺乳动物slc6a19功能的小分子抑制剂

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241226

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250307

R150 Certificate of patent or registration of utility model

Ref document number: 7649386

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150